Enerceuticals™ and the Alternative Cellular Energy (ACE) Pathway
W. John Martin, MD, PhD
Institute of Progressive Medicine
Progressive University
While enormous strides have been made in defining the biochemical basis for many disease processes, effective pharmaceutical-based therapies for various common illnesses remain elusive. All too often a pharmaceutical drug is formulated to inhibit a specific metabolic aberration that characterizes a particular disease, only to realize that the drug has untoward side effects. In some situations, this realization comes after the drug has been approved for marketing by the Food and Drug Administration (FDA).
A more progressive view of medicine interprets symptoms of many diseases as expressions of the body’s attempts to optimally adapt to an underlying disorder (1). The adaptation is best considered a reflection of the body’s innate healing response rather than a process to be undermined using a pharmaceutical drug.
Precise details of the complex metabolic processes occurring in living cells and changes occurring in various disease states are exciting topics of informative biochemical research. Even without such detailed knowledge, however, it is reasonable to presume that optimal functioning of the body, including engaging in any reparative adaptation to a disease, requires an adequate source of cellular energy.
The body’s energy supply is commonly perceived as coming solely from the extraction of chemical energy from nutrients provided in foods. Within animal and human cells, most of the chemical energy is obtained by the directed channeling of food-derived electrons and protons to oxygen molecules within organelles called mitochondria. This metabolic process leads to the formation of water and carbon dioxide along with a steady supply of adenosine triphosphate (ATP) from adenosine diphosphate (ADP).
Viruses exist that lack the relatively few critical antigenic targets required for an effective anti-viral cellular immune response (2-11). They have been generically grouped under the term “stealth-adapted.” Such viruses fail to evoke a typical inflammatory response in patients or in inoculated animals. Yet the diseases caused by these viruses are typically of a chronic nature with periods of clinical improvements in spite of the lack of a cellular immune response. A striking feature of stealth adapted virus infected cells is the marked disruption of mitochondria (12).
Studies on stealth adapted viruses led to the identification of an auxiliary repair process mediated by mineral containing organic structures termed alternative cellular energy (ACE) pigments (12, 13). Through a self-assembly process, various particles and fibers develop in virus cultures that are strikingly auto-fluorescent, electrostatic, and occasionally magnetic. Most importantly, they can mediate electron transfer reactions (13). They also appear to have biosynthetic properties leading to the formation of lipid-like materials in the form of membranes, shallow elongated troughs and pyramids (13, 14).
Various types of naturally occurring and synthetic materials were examined for ACE activity using repair of virus infected cells as one of several criteria. Included in the testing were certain commercial products currently in use to promote the vitality of plants. These include humic and fulvic acids, zeolites and plant extracts containing essential oils (terpenes). Also included were various tonics and dietary supplements advocated for human use, as well as a supposedly homeopathic preparation that contained undisclosed ingredients readily identified using gas chromatography – mass spectroscopy (GC:MS analysis).
The term “enerceutical” was trademarked to clearly distinguish ACE products from pharmaceuticals. The distinction is important in that the FDA is primarily concerned with pharmaceuticals, which are intended to prevent or treat specific diseases. The FDA is less involved with products that enhance normal physiological functions. The three defining characteristics of enerceuticals are: i) They are not designed or intended to treat a particular disease. Indeed, enerceuticals can be used as much to enhance the performance of a star athlete as assist an individual to better cope with one or more energy draining illness. ii) Enerceuticals are effective tonics for plants as well as benefiting humans and animals. iii) Most importantly, enerceuticals do not necessarily have to reach every cell to provide overall benefits. Rather they can operate by creating a transmissible field of biological energy by utilizing a source of physical energy. The beneficial effects can, therefore, extend well beyond the physical location of the enerceutical. Several enerceutical based products are, accordingly, being formulated as skin appearance enhancing cosmetics.
Medical practitioners are being sought to help extend these studies by personally consuming and/or applying various enerceutical products and noting what, if any, physiological changes become apparent. Incidental observations on any disease process will be of additional interest. Markers could include overall energy levels, recovery times from strenuous exercise, improved sleep and mental alertness, and possible reduced requirements for any medications, such as hypertension or blood sugar lowering agents. Several products are currently available for assessment and can be provided at or near the cost to the Institute of Progressive Medicine. Interested practitioners will be randomly assigned to evaluate a given product and will be asked to report his or her findings to an impartial statistician, unaware of the actual products being tested. A summary of the findings will be provided to all participants. Please direct your willingness to assist in this endeavor to W. John Martin at 626-616-2868 or via e-mail to progressiveuniversity@yahoo.com
References
1. Martin WJ. Progressive Medicine. Exp Mol Path 78: 218-220, 2005.
2. Martin WJ, Zeng LC, Ahmed K, Roy M. Cytomegalovirus‑related sequences in an atypical cytopathic virus repeatedly isolated from a patient with the chronic fatigue syndrome. Am. J. Path. 145: 441‑452, 1994.
3. Martin WJ. Stealth virus isolated from an autistic child. J. Aut. Dev. Dis. 25:223‑224,1995
4. Martin WJ, Ahmed KN, Zeng LC, Olsen J‑C, Seward JG, Seehrai JS. African green monkey origin of the atypical cytopathic 'stealth virus' isolated from a patient with chronic fatigue syndrome. Clin. Diag. Virol. 4: 93‑103, 1995.
5. Martin WJ, Glass RT. Acute encephalopathy induced in cats with a stealth virus isolated from a patient with chronic fatigue syndrome. Pathobiology 63: 115‑118, 1995.
6. Martin WJ. Severe stealth virus encephalopathy following chronic fatigue syndrome‑like illness: Clinical and histopathological features. Pathobiology 64:1‑8, 1996.
7. Martin WJ. Stealth viral encephalopathy: Report of a fatal case complicated by cerebral vasculitis. Pathobiology 64:59‑63, 1996.
8. Martin WJ. Simian cytomegalovirus‑related stealth virus isolated from the cerebrospinal fluid of a patient with bipolar psychosis and acute encephalopathy. Pathobiology 64:64‑66, 1996.
9. Martin WJ, Anderson D: Stealth virus epidemic in the Mohave Valley. Initial report of viral isolation. Pathobiology 65:51-56, 1997.
10. Martin WJ. Stealth adaptation of an African green monkey simian cytomegalovirus. Exp Mol Path. 66:3-7, 1999.
11. Martin WJ, Anderson D. Stealth Virus Epidemic in the Mohave Valley: Severe vacuolating encephalopathy in a child presenting with a behavioral disorder. Exp Mol Pathol. 66:19-30 1999.
12. Martin WJ. Complex intracellular inclusions in the brain of a child with a
stealth virus encephalopathy. Exp Mol Path 74: 179-209, 2003.
13. Martin WJ. Stealth virus culture pigments: A potential source of cellular energy.
Exp. Mol. Path. 74: 210-223, 2003.
14. Martin WJ. Etheric Biology. Exp Mol Path 78: 221-227, 2005.